Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Vifor Pharma
Publication of definitive end result for Vifor Pharma tender offer
March 28, 2022
From
Vifor Pharma
Via
Business Wire
Vifor Pharma reports sustained growth in 2021
February 17, 2022
From
Vifor Pharma
Via
Business Wire
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
December 21, 2021
From
Vifor Pharma
Via
Business Wire
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
December 10, 2021
From
Vifor Pharma
Via
Business Wire
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
December 10, 2021
From
Vifor Pharma
Via
Business Wire
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
December 10, 2021
From
Vifor Pharma
Via
Business Wire
Tickers
ANGN
Vifor Pharma announces changes to the Executive Committee as CFO retires
November 30, 2021
From
Vifor Pharma
Via
Business Wire
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
November 22, 2021
From
Vifor Pharma
Via
Business Wire
Vifor Pharma announces changes to its Executive Committee
October 12, 2021
From
Vifor Pharma
Via
Business Wire
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1
August 05, 2021
From
Vifor Pharma
Via
Business Wire
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
June 24, 2021
From
Vifor Pharma
Via
Business Wire
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
June 24, 2021
From
Vifor Pharma
Via
Business Wire
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
April 29, 2021
From
Vifor Pharma
Via
Business Wire
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
April 28, 2021
From
Vifor Pharma
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.